ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
Go back to ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform| (NASDAQ: PRQR) | Delayed: 1.83 -0.06 (3.17%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.89 | 52 Week High | $13.33 | |||
| Open | $1.89 | 52 Week Low | $3.48 | |||
| Day High | $1.89 | P/E | N/A | |||
| Day Low | $1.83 | EPS | $0.00 | |||
| Volume | 569,284 | |||||
